Posted on

Written by Sheena Beronio

Cannaray, a UK-based medical cannabis company, announced that the first UK cannabis prescription was successfully administered on a toddler named Jorja Emerson, who is a three-year-old British girl with severe epilepsy.

This success was made possible through Aphria Inc., one of the world’s leading cannabis companies and Cannaray’s partnership. Aphria has advanced cannabis formulations and delivery systems at par with European medical standards that are currently not publicly accessible.

Cannaray, through the mouth of their CEO, Scott Maguire, is all in for providing patients who are in dire need of cannabis treatment. Cannaray is pleased with the thought of helping patients like Jorja and many more in the future.

“Working with the medical community to provide specialist support and access to cannabis-based drugs for patients in dire need of this treatment is fundamental to our strategy. We are pleased to assist Robin in accessing treatment for his daughter, and we will continue to drive for broader and continuous cannabis access for patients,” as per Maguire.

Robin Emerson, Jorja’s father, was appointed as Cannaray’s first Director of Patient Support. His job is to give support and offer solutions to families seeking cannabis prescriptions as well as those who are undergoing cannabis treatment.

“I am delighted to join the Cannaray team in being able to bring real-world knowledge for the company to understand the patient’s needs and requirements,” said Emerson.

Cannaray’s Expansion

Recently, Cannaray appointed Gregor Zorn as the company’s newest Chief Scientific Officer. Gregor is one of the major leagues in medical cannabis research and development, and his career in Medical Cannabis Research spans years.

“Improvements in technology and dedicated research have allowed us to start understanding the full potential of this healing plant. I am honored to be joining this amazing team of professionals, and I am looking forward to adding my expertise in achieving Cannaray’s vision of providing patients with the best medical cannabis and cannabinoid-based products,” said Zorn.

Aside from Zorn, Cannaray has a Scientific Advisory Board that’s comprised of specialists who covers the major five areas of medical cannabis use; Multiple Sclerosis, Chemo-Induced Nausea, and Vomiting, Epilepsy, Chronic Pain and Tourettes.

The UK made medicinal cannabis accessible to patients in November 2018 through supervision from specialist doctors. Recently, UK medical experts were given the power to issue prescriptions on cannabis-based medicine.

Before the ruling on prescriptive medicinal cannabis, almost all cannabis-based products were ruled to have no therapeutic value.